Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Plus Pembrolizumab as Maintenance Therapy in NSCLC (ZEAL-1L)
NCT04475939Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of niraparib in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Oct 2020; status: completed.
02
Drugs
niraparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04475939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04475939.